Spero Therapeutics Stock Market Outlook
| SPRO Stock | USD 2.37 0.01 0.42% |
About 52% of Spero Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Spero Therapeutics suggests that some traders are interested. Spero Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Spero Therapeutics. Many technical investors use Spero Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 52
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Spero Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Spero Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Spero Therapeutics is 'Hold'. The recommendation algorithm takes into account all of Spero Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Execute Spero Therapeutics Advice
The Spero recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Spero Therapeutics. Macroaxis does not own or have any residual interests in Spero Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Spero Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Weakest | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Spero Therapeutics has a Risk Adjusted Performance of 0.0145, Jensen Alpha of (0.13), Total Risk Alpha of (0.31), Sortino Ratio of (0.03) and Treynor Ratio of 0.0102We provide advice to complement the current expert consensus on Spero Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Spero Therapeutics is not overpriced, please validate all Spero Therapeutics fundamentals, including its price to earning, book value per share, current liabilities, as well as the relationship between the net income and beta . Please also confirm Spero Therapeutics number of shares shorted to double-check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Spero Therapeutics Trading Alerts and Improvement Suggestions
| Spero Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 47.98 M. Net Loss for the year was (68.57 M) with loss before overhead, payroll, taxes, and interest of (21.16 M). | |
| Spero Therapeutics currently holds about 45.4 M in cash with (23.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Spero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Spero Therapeutics CEO sells 207k in stock - Investing.com |
Spero Therapeutics Returns Distribution Density
The distribution of Spero Therapeutics' historical returns is an attempt to chart the uncertainty of Spero Therapeutics' future price movements. The chart of the probability distribution of Spero Therapeutics daily returns describes the distribution of returns around its average expected value. We use Spero Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Spero Therapeutics returns is essential to provide solid investment analysis for Spero Therapeutics.
| Mean Return | 0.03 | Value At Risk | -5.04 | Potential Upside | 3.81 | Standard Deviation | 2.79 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Spero Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Spero Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Spero Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Spero Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-06-30 | 153.5 K | Ionic Capital Management Llc | 2025-06-30 | 150 K | Adar1 Capital Management Llc | 2025-06-30 | 143.9 K | Bridgeway Capital Management, Llc | 2025-06-30 | 114.8 K | Citadel Advisors Llc | 2025-06-30 | 103.8 K | Northern Trust Corp | 2025-06-30 | 100.8 K | Susquehanna International Group, Llp | 2025-06-30 | 69.8 K | Xtx Topco Ltd | 2025-06-30 | 34.6 K | Axxcess Wealth Management, Llc | 2025-06-30 | 32.5 K | Pfizer Inc | 2025-06-30 | 2.4 M | Vanguard Group Inc | 2025-06-30 | 2 M |
Spero Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 27.4M | (3.5M) | (32.8M) | (23.4M) | (21.1M) | (20.0M) | |
| Free Cash Flow | (64.3M) | (7.7M) | (33.0M) | (23.4M) | (21.1M) | (22.2M) | |
| Depreciation | 1.1M | 1.5M | 367K | 2K | 2.3K | 2.2K | |
| Other Non Cash Items | 11.4M | 15.1M | 6.3M | 1.0M | 1.2M | 1.1M | |
| Net Income | (89.8M) | (46.4M) | 22.8M | (68.6M) | (61.7M) | (64.8M) | |
| End Period Cash Flow | 112.6M | 109.1M | 76.3M | 52.9M | 60.8M | 66.4M | |
| Change To Netincome | 3.7M | 4.6M | 11.9M | 15.7M | 18.1M | 19.0M |
Spero Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Spero Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Spero Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Spero stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 1.55 | |
σ | Overall volatility | 2.59 | |
Ir | Information ratio | -0.03 |
Spero Therapeutics Volatility Alert
Spero Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Spero Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Spero Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Spero Therapeutics Fundamentals Vs Peers
Comparing Spero Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Spero Therapeutics' direct or indirect competition across all of the common fundamentals between Spero Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Spero Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Spero Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Spero Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Spero Therapeutics to competition |
| Fundamentals | Spero Therapeutics | Peer Average |
| Return On Equity | -0.95 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Profit Margin | (1.08) % | (1.27) % |
| Operating Margin | (1.35) % | (5.51) % |
| Current Valuation | 88.26 M | 16.62 B |
| Shares Outstanding | 56.34 M | 571.82 M |
| Shares Owned By Insiders | 23.34 % | 10.09 % |
| Shares Owned By Institutions | 16.52 % | 39.21 % |
| Number Of Shares Shorted | 941.66 K | 4.71 M |
| Price To Earning | 81.20 X | 28.72 X |
| Price To Book | 5.04 X | 9.51 X |
| Price To Sales | 3.28 X | 11.42 X |
| Revenue | 47.98 M | 9.43 B |
| Gross Profit | (21.16 M) | 27.38 B |
| EBITDA | (72.48 M) | 3.9 B |
| Net Income | (68.57 M) | 570.98 M |
| Cash And Equivalents | 45.4 M | 2.7 B |
| Cash Per Share | 1.29 X | 5.01 X |
| Total Debt | 4.3 M | 5.32 B |
| Debt To Equity | 0.19 % | 48.70 % |
| Current Ratio | 3.65 X | 2.16 X |
| Book Value Per Share | 0.47 X | 1.93 K |
| Cash Flow From Operations | (23.44 M) | 971.22 M |
| Short Ratio | 4.03 X | 4.00 X |
| Earnings Per Share | (0.79) X | 3.12 X |
| Target Price | 4.0 | |
| Number Of Employees | 32 | 18.84 K |
| Beta | 1.45 | -0.15 |
| Market Capitalization | 132.96 M | 19.03 B |
| Total Asset | 110.54 M | 29.47 B |
| Retained Earnings | (459.64 M) | 9.33 B |
| Working Capital | 58.2 M | 1.48 B |
| Current Asset | 7.3 M | 9.34 B |
Note: Disposition of 18652 shares by Timothy Keutzer of Spero Therapeutics at 2.36 subject to Rule 16b-3 [view details]
Spero Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Spero . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 6188.47 | |||
| Daily Balance Of Power | 0.0909 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 2.38 | |||
| Day Typical Price | 2.37 | |||
| Period Momentum Indicator | 0.01 |
About Spero Therapeutics Buy or Sell Advice
When is the right time to buy or sell Spero Therapeutics? Buying financial instruments such as Spero Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Spero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 335 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Spero Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.